ABSTRACT:
ABSTRACT:
In recent years, significant advancements have been made in drug delivery systems, particularly through the use of innovative microparticulate carriers such as microemulsions, nanoemulsions, nanoparticles, liposomes, and ethosomes. These systems have been extensively studied for their ability to enhance the delivery of both hydrophilic and hydrophobic drugs, improving therapeutic efficacy. Liposomes, which are phospholipid-based vesicles that self-assemble into bilayers, have emerged as a promising drug delivery system. Their ability to encapsulate active agents within a central aqueous compartment makes them suitable for targeted drug delivery.
In this study, Rabeprazole sodium, a BCS Class III drug, was encapsulated into liposomes to improve its bioavailability and efficacy in treating Gastroesophageal Reflux Disease (GERD). Rabeprazole sodium, being hydrophilic, presents challenges in absorption, which makes liposomal delivery a valuable approach for enhancing its therapeutic potential. The formulation process was guided by Design Expert software, utilizing a 2² central composite design to optimize the formulation. A total of 13 experimental runs were conducted, which allowed for the identification of an optimized liposomal formulation. This optimized formulation offers a promising strategy for improving drug delivery, targeting, and bioavailability, which could lead to more effective treatment of GERD. This research underscores the potential of liposomal drug delivery systems in enhancing the treatment of GERD and highlights the importance of design software in optimizing pharmaceutical formulations for improved clinical outcomes.
Cite this article:
J Adlin Jino Nesalin, Chidananda B N. Formulation and Optimization of Rabeprazole Sodium-Loaded Liposomes using Design Expert Software. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(3):237-4. doi: 10.52711/2231-5659.2025.00036
Cite(Electronic):
J Adlin Jino Nesalin, Chidananda B N. Formulation and Optimization of Rabeprazole Sodium-Loaded Liposomes using Design Expert Software. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(3):237-4. doi: 10.52711/2231-5659.2025.00036 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-3-3
REFERENCE:
1. Tan ML, Choong PF, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides. 2010; 31(1): 184-193.
2. Dunnhaupt S, Kammona O, Waldner C, Kiparissides C. A. Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur J Pharm Biopharm. 2015; 96(3): 447-53.
3. Kanasova M, Nesmerak K. Systematic review of liposomes characterization methods. Monatsh Chem. 2017; 148(2): 1581-93.
4. Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am. J. Med. 1998 Mar 1; 104(3): 252-8
5. Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Missouri medicine. 2018 May; 115(3): 214.
6. Kellerman R, Kintanar T. Gastroesophageal reflux disease. Primary care. 2017 Oct 5; 44(4): 561-73.
7. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun 1;63(6):871-80.
8. Scarpignato C, Hongo M, Wu JC, Lottrup C. Pharmacologic treatment of GERD: Where we are now, and where are we going? Annals of the New York Academy of Sciences. 2020 Dec; 1482(1): 193-212.
9. Rackoff A, Agrawal A, Hila A. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Diseases of the Esophagus.2005 Dec 1;18(6): 370-3
10. Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nature Reviews Gastroenterology & Hepatology. 2017 Dec; 14(12): 697-710.
11. Manish G, Vimukta S. Targeted drug delivery system: a review. Res J Chem Sci. 2011 May; 1(2): 135-8.
12. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews. 2013 Jan 1;65(1):36-48.
13. J.S. Dua, A. C. Rana, A. K. Bhandari. Liposome: Methods of preparation and applications. IJPSR 2012;3(2):14-20.
14. Bhattacharya S. Central composite design for response surface methodology and its application in pharmacy. Response Surface Methodology in Engineering Science 2021 Jan 28. IntechOpen
15. Sopyan IY, Gozali DO, Guntina RK. Design-expert software (DOE): An application tool for optimization in pharmaceutical preparations formulation. Int. J. Appl. Pharm. 2022:55-63.
16. Kumari M, Jain NP. Formulation Development & Evaluation of Buffered Tablet of Proton Pump Inhibitors Drug Rabeprazole Sodium. JDDT. 2019 Aug 15; 9(4-s): 315-21.
17. Bhavani k, matsyagiri l. Formulation and in vitro evaluation of rabeprazole sodium delayed release tablets.
18. Njoku CN, Otisi SK. Application of central composite design with design expert v13 in process optimization. InResponse Surface Methodology-Research Advances and Applications 2023 Jan 23. IntechOpen
19. Patel P M, Desai H J, Patel R C. Spectrophotometric method for estimation of rabeprazole, of Indian J. Pharm. Sci. 2007; 69(2): 318- 320.
20. Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. Journal of Pharmaceutical and Biomedical Analysis. 2021 Jan 5; 192: 113642.
21. Kaszuba M, Corbett J, Watson FM, et., al. High-concentration zeta potential measurements using light-scattering techniques. Philosophical transactions of the Royal Society a: Mathematical, Physical and Engineering Sciences. 2010 Sep 28; 368(1927): 4439-51.
22. Ran C, Chen D, Xu M, et. al. A study on characteristic of different sample pretreatment methods to evaluate the entrapment efficiency of liposomes. Journal of Chromatography B. 2016 Aug 15; 1028: 56-62.